IGFBP7 and acute kidney injury: Interestingly, the FDA approved test “NephroCheck®”, which is in clinical use and predicts the risk of developing moderate to severe AKI within 24 h [52], uses the following two biomarkers: tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7).